MYCN and neuroblastoma: Inhibitors of PLK1, such as BI6727 and BI2356, preferentially trigger apoptosis of MYCN-amplified neuroblastoma and small cell lung cancer, and this therapeutic efficacy is synergistically enhanced by combined use with antagonists of anti-apoptotic B cell lymphoma 2 (BCL2) (128).